TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.
Company profile
Ticker
TXMD
Exchange
Website
CEO
Robert Finizio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
SEC CIK
Corporate docs
Subsidiaries
VitaMedMD, LLC • BocagreenMD, Inc. • VitaCare Prescription Services, Inc. ...
IRS number
870233535
TXMD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
27 Feb 23
8-K
Departure of Directors or Certain Officers
18 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jan 23
8-K/A
Departure of Directors or Certain Officers
6 Jan 23
8-K
TherapeuticsMD Completes Transaction to License its Products to Mayne Pharma
3 Jan 23
8-K
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
5 Dec 22
8-K
Entry into a Material Definitive Agreement
1 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
D
$7.00 mm in equity / options / securities to be acquired, sold $7.00 mm, 6 investors
14 Nov 22
8-K
TherapeuticsMD Announces Third Quarter 2022 Financial Results
14 Nov 22
Transcripts
TXMD
Earnings call transcript
2022 Q2
15 Aug 22
TXMD
Earnings call transcript
2022 Q1
17 May 22
TXMD
Earnings call transcript
2021 Q4
10 Mar 22
TXMD
Earnings call transcript
2021 Q3
11 Nov 21
TXMD
Earnings call transcript
2021 Q2
4 Aug 21
TXMD
Earnings call transcript
2021 Q1
6 May 21
TXMD
Earnings call transcript
2020 Q4
2 Mar 21
TXMD
Earnings call transcript
2020 Q3
9 Nov 20
TXMD
Earnings call transcript
2020 Q2
7 Aug 20
TXMD
Earnings call transcript
2020 Q1
6 May 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 38.33 mm | 38.33 mm | 38.33 mm | 38.33 mm | 38.33 mm | 38.33 mm |
| Cash burn (monthly) | (no burn) | 5.54 mm | 9.74 mm | 697.92 k | 6.31 mm | 8.62 mm |
| Cash used (since last report) | n/a | 33.20 mm | 58.35 mm | 4.18 mm | 37.77 mm | 51.61 mm |
| Cash remaining | n/a | 5.13 mm | -20.02 mm | 34.15 mm | 555.93 k | -13.28 mm |
| Runway (months of cash) | n/a | 0.9 | -2.1 | 48.9 | 0.1 | -1.5 |
Institutional ownership, Q4 2022
15.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 48 |
| Opened positions | 12 |
| Closed positions | 10 |
| Increased positions | 11 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 18.74 bn |
| Total shares | 35.49 mm |
| Total puts | 228.10 k |
| Total calls | 95.26 k |
| Total put/call ratio | 2.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Flynn James E | 20.66 mm | $23.14 mm |
| Smith Robert J | 11.35 mm | $0.00 |
| Rubric Capital Management | 1.76 mm | $9.82 bn |
| Vanguard | 385.25 k | $2.15 bn |
| Tejara Capital | 317.31 k | $1.77 bn |
| Clearline Capital | 234.04 k | $1.31 bn |
| MS Morgan Stanley | 133.48 k | $746.16 mm |
| BLK Blackrock | 116.13 k | $649.18 mm |
| Susquehanna International | 82.88 k | $463.28 mm |
| Geode Capital Management | 66.95 k | $374.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Feb 23 | Donegan Michael C | RSU Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |
| 21 Feb 23 | Marlan D Walker | RSU Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 70,000 |
| 27 Jan 23 | Donegan Michael C | Common Stock | Sell | Dispose S | No | No | 5.09 | 49 | 249.41 | 11,853 |
| 26 Jan 23 | Donegan Michael C | Common Stock | Sell | Dispose S | No | No | 5.0796 | 1,648 | 8.37 k | 11,902 |
| 26 Jan 23 | Donegan Michael C | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,140 | 0.00 | 13,550 |
| 26 Jan 23 | Donegan Michael C | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,400 | 0.00 | 12,410 |
| 26 Jan 23 | Donegan Michael C | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,400 | 0.00 | 10,010 |
| 26 Jan 23 | Donegan Michael C | Performance Stock Units Common Stock | Option exercise | Dispose M | No | No | 0 | 1,140 | 0.00 | 0 |
| 26 Jan 23 | Donegan Michael C | Performance Stock Units Common Stock | Option exercise | Dispose M | No | No | 0 | 2,400 | 0.00 | 0 |
| 26 Jan 23 | Donegan Michael C | Performance Stock Units Common Stock | Option exercise | Dispose M | No | No | 0 | 2,400 | 0.00 | 0 |
News
Cigna Is Out With A New Coverage Policy Stating That TherapeuticsMD Imvexxy Is Now Covered. (Effective 1/1/24 But Just Disclosed).
27 Jan 23
Cantor Fitzgerald Reinstates Neutral on TherapeuticsMD, Announces $5 Price Target
11 Jan 23
12 Health Care Stocks Moving In Monday's After-Market Session
2 Jan 23